The talk of the show?

Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPHI WW.
Ahead of CPHI Worldwide in Frankfurt next week, Barbara Morgan, Pharmaceutical Business Director at Lubrizol Life Science Health discusses the trends she expects to be the talk of the show.
What do you think will be the major trends and talking points at CPHI Worldwide 2019?
We expect to see a continuation of the growing trend of outsourcing the full spectrum of pharmaceutical services, including commercial manufacturing. Recent figures show that only around one third of manufacturing — whether in the development stages or after commercial launch — is conducted in-house. This year, we have invested in our own commercial manufacturing capabilities with the opening of a new commercial manufacturing facility which is now up and running and recently produced its first set of three registration batches.
The ongoing growth of the biologics market over the past few years will likely be reflected on the show floor, particularly as 2019 has witnessed the FDA releasing guidelines on how biosimilars can achieve an interchangeable status and substitute the reference biologic without a prescriber intervening.
There has also been much discussion this year about the pricing pressures on generics, with regulators, patients and politicians seeking to drive down prices.
In terms of drug development trends, we expect to see an increased focus on long-acting products such as microparticle depots and implants as drug developers seek dosage forms that can aid better patient compliance. This is a topic we are keen to discuss with visitors to our stand.
What is your company hoping to achieve at this year's event?
This year we’re hoping to engage in discussions that center around GMP for clinical trial supply and commercial manufacturing. Lubrizol Life Science Health is currently well known for its focus on complex drug development projects. We’re keen to expand our client base and engage with those who are not yet familiar with our unique capabilities around commercial manufacturing of small batch size products.
What do you most look forward to about CPHI?
I enjoy how well-organized and efficient the CPHI Worldwide event is and the fact that it brings so many people in the industry together, giving you an opportunity to catch up with those clients that you don’t often see in person. It also provides a great environment for meeting new clients and prospects and learning more about the latest trends and talking points in the industry among like-minded peers.
Any presentations/events or news you'd like to tell us about?
This year our big announcement is that we will be changing our name from Particle Sciences to Lubrizol Life Science Health. The name change is an outward sign of our official transition under the Lubrizol Life Science brand umbrella.
As part of Lubrizol Life Science, we can share and draw upon the resources that come with being part of a large corporation, providing customers with greater support and market insights that help them meet their goals.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance